Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Journal of Clinical Oncology

Volumn 29, Issue 7, 2011, Pages 917-924

  Robbins, Paul F ^a   Morgan, Richard A ^a   Feldman, Steven A ^a   Yang, James C ^a   Sherry, Richard M ^a   Dudley, Mark E ^a   Wunderlich, John R ^a   Nahvi, Azam V ^a   Helman, Lee J ^a   Mackall, Crystal L ^a   Kammula, Udai S ^a   Hughes, Marybeth S ^a   Restifo, Nicholas P ^a   Raffeld, Mark ^a   Lee, Chyi Chia Richard ^a   Levy, Catherine L ^a   Li, Yong F ^a   El Gamil, Mona ^a   Schwarz, Susan L ^a   Laurencot, Carolyn ^a   Rosenberg, Steven A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 2; LEXATUMUMAB; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; TRABECTEDIN; VINBLASTINE; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; FEMALE; GENETIC ENGINEERING; HUMAN; MALE; MELANOMA; METASTATIC SYNOVIAL CELL SARCOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SARCOMA; TREATMENT RESPONSE;

ADULT; CANCER VACCINES; EPIGENESIS, GENETIC; FEMALE; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SARCOMA, SYNOVIAL; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952304769     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.2537     Document Type: Article

References (26)

1. Dudley ME, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239, 2008
2. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240, 2009
3. Tran KQ, Zhou J, Durflinger KH, et al: Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 31:742-751, 2008
4. Morgan RA, Dudley ME, Wunderlich JR, et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129, 2006 (Pubitemid 44547756)
5. Johnson LA, Morgan RA, Dudley ME, et al: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546, 2009
6. Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914-1918, 1997
7. Barrow C, Browning J, MacGregor D, et al: Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:764-771, 2006 (Pubitemid 43259856)
8. Goydos JS, Patel M, Shih W: NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res 98:76-80, 2001 (Pubitemid 32548071)
9. Gure AO, Chua R, Williamson B, et al: Cancertestis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11:8055-8062, 2005 (Pubitemid 41698748)
10. Jungbluth AA, Antonescu CR, Busam KJ, et al: Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 94:252-256, 2001 (Pubitemid 32911421)
11. Vaughan HA, Svobodova S, Macgregor D, et al: Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10:8396-8404, 2004 (Pubitemid 40053402)
12. Robbins PF, Li YF, El-Gamil M, et al: Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 180:6116-6131, 2008
13. Goff SL, Robbins PF, El-Gamil M, et al: No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma. J Immunother 32:884-885, 2009
14. Burns WR, Zheng Z, Rosenberg SA, et al: Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114:2888-2899, 2009
15. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005 (Pubitemid 46218728)
16. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703, 2008 (Pubitemid 351860862)
17. Pule MA, Savoldo B, Myers GD, et al: Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264-1270, 2008
18. Lamers CH, Langeveld SC, Groot-van Ruijven CM, et al: Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 56:1875-1883, 2007
19. Kershaw MH, Westwood JA, Parker LL, et al: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106-6115, 2006 (Pubitemid 44703776)
20. Bender A, Karbach J, Neumann A, et al: LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun 7:16, 2007
21. Odunsi K, Qian F, Matsuzaki J, et al: Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 104:12837-12842, 2007 (Pubitemid 47255241)
22. Jäger E, Karbach J, Gnjatic S, et al: Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 103:14453-14458, 2006 (Pubitemid 44484771)
23. Nicholaou T, Ebert LM, Davis ID, et al: Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 15:2166-2173, 2009
24. Caballero OL, Chen YT: Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 100:2014-2021, 2009
25. Fred Hutchinson Cancer Research Center: Patient's own infection-fighting T cells put late-stage melanoma into long-term remission - without chemotherapy or radiation. http://www.fhcrc.org/about/ne/news/2008/06/18/T-cells.html
26. Kerkar SP, Muranski P, Kaiser A, et al: Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lympho-depleted hosts. Cancer Res 70:6725-6734, 2010